Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

johnson & johnson, s.r.o., slovensko - topiramát - 21 - antiepileptica, anticonvulsiva

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

johnson & johnson, s.r.o., slovensko - topiramát - 21 - antiepileptica, anticonvulsiva

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

mcneil healthcare (ireland) limited, Írsko - cetirizín - 24 - antihistaminica, histamin

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

johnson & johnson, s.r.o., slovensko - risperidón - 68 - antipsychotica (neuroleptica)

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

johnson & johnson, s.r.o., slovensko - risperidón - 68 - antipsychotica (neuroleptica)

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

johnson & johnson, s.r.o., slovensko - risperidón - 68 - antipsychotica (neuroleptica)

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

mcneil healthcare (ireland) limited, Írsko - loperamid - 49 - digestiva, adsorbentia, acida

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

mcneil healthcare (ireland) limited, Írsko - loperamid, kombinácie - 49 - digestiva, adsorbentia, acida

Európska únia - slovenčina - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vakcíny - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. použitie tejto vakcíny by mali byť v súlade s oficiálne odporúčania.

Európska únia - slovenčina - EMA (European Medicines Agency)

baxter holding b.v. - hydrochlorid doxorubicínu - sarcoma, kaposi; multiple myeloma; ovarian neoplasms; breast neoplasms - antineoplastické činidlá - caelyx pegylated liposomal je uvedené:ako monotherapy pre pacientov s metastatického karcinómu prsníka, tam, kde je zvýšené riziko srdcového;na liečbu pokročilej rakoviny vaječníkov u žien, ktorí neuspeli v prvom riadku platinum-založené chemoterapia režim;v kombinácii s bortezomib na liečbu progresívneho myelómom je mladších u pacientov, ktorí dostali aspoň jeden pred terapiou a ktorí už podstúpili alebo sú nevhodné pre kostnej drene sa transplantácia;pre liečbu aids súvisiace s kaposiho sarkóm (ks) u pacientov s nízkym počtom cd4 (.